Corporate Finance & Advisory, International Trade & Development, and Investor Relations

Est. 1989


  • GC Partners has been active in the healthcare, biotech and healthtech since its establishment in 1989
  • GC Partners has developed relationships throughout Australia, Asia, Europe and the U.S. with public and private hospitals and health check clinics, specialist clinics, pharma, biotech, medical technology, academic institutions, regional associations & societies, medical device, and equipment companies
  • Developments in technology are moving rapidly and over the next 50 years healthcare investment and expenditures will increase substantially
  • The Australian Government is investing in a stronger health system as part of its plan for a stronger future through a record AUD132 billion in 2022–23, increasing to AUD140 billion in 2025–26, with a total commitment of AUD537 billion over the next four years.

Healthcare & Life Sciences

  • Australia’s fast-growing life sciences sector is one of the largest in the southern hemisphere. It’s worth more than AUD250 billion and home to more than 2,600+ organisations
  • Australia’s high-quality and innovative healthcare system is envied around the world. It’s underpinned by a world-class medical research sector, nurtured in our universities and hospitals, medical research institutes and life science companies.


“Australia - a thriving lifescience hub with potential for global reach…”

  • The global biotechnology sector provides social and economic opportunities and benefits. The market is forecast to grow to USD1040 billion by 2030, registering a compound annual growth rate of 7.5% to 2030
  • Australia has a strong base in biotechnology, with many incentives for R&D and commercialisation. Health and medical research is one of Australia’s strongest research sectors
  • Australia has unique strengths in undertaking clinical trials to test the efficacy and safety of medical products. Australia’s health system is also one of the most efficient and equitable in the world, ranking in the top 10 globally
  • The Australian Government will continue to support all parts of the research and development pipeline. It provides incentives to grow Australian sovereign capacity and capability to research and manufacture locally while embedding into a growing international supply-chain for advanced medical products
  • The global In Vitro Diagnostics market is expected to reach USD130 billion at a CAGR of 4.6% from 2023 to 2030
  • Australia companies have been slow to take advantage of Asia and Europe in the collaboration and commercialisation of research.

“Australia - a thriving lifescience hub with potential for global reach…”

Opportunities in Asian Healthcare and Life Sciences

  • There are clear opportunities in the Asian region for Australian pharma and life science companies looking to secure investors for funding and collaboration partners for research and commercialisation
  • Companies are seeking an integrated way of working together which involves sharing of skills, resources, infrastructure, and exclusive knowledge, whilst overall care delivery remains fragmented and diverse
  • Home to more than 60% of the global population, the Asia-Pacific (APAC) region presents an immense commercial opportunity for biopharma, medical device, and healthcare companies. For these life sciences enterprises, APAC also offers highly attractive market entry prospects. Regional healthcare expenditure in APAC is projected to grow and outpace growth in the U.S. and Europe
  • By 2050, more than a quarter – or 1.3 billion – of the population in Asia Pacific will be considered elderly, or 60 years or older
  • APAC countries with advanced reimbursement systems or improving healthcare infrastructure have also emerged as lucrative markets. These include countries such as mainland China, Japan, Taiwan, Korea, Australia, Singapore, Indonesia, and Thailand
  • In 2021, China’s total healthcare expenditure reached RMB 7.6 trillion (approx. USD1.2 trillion), more than doubling from 2015.

Opportunities in UK & European Life Sciences & Biotechnology

  • Biotechnology companies are increasingly taking on the task of commercialisation. The European market holds USD246 billion potential and many biotech companies are now building a footprint there
  • Europe remains an important market for launching new drugs, as it accounts for over 20 per cent of the total global pharma market
  • It comprises thirty one markets across Europe, including the UK and Switzerland
  • Oncology is the leading therapeutic area for emerging biotech products
  • Europe boasts its own set of hot spots for biotech and biopharma development
  • The growth of the European health care market and the growing acceptance of tech solutions in health care fuel the demand for healthtech solutions. An existing skills shortages mean there is extra room for outsourcing solutions and products.